Edwards Lifesciences Corporation (EW), a global leader in the field of heart valve therapies, has seen considerable activity recently. Many firms, including
US Bancorp DE and
Mirova US LLC, have increased their stake in EW, while others like
Vontobel Holding Ltd. and
Baxter Bros Inc. have reduced their holdings. The company recently received
upgrade ratings from
Evercore ISI Group, however, was downgraded at Oppenheimer. Amidst this, the company has seen
strong sales growth boosting its Q2 2025 earnings. EW also announced a $500 million
accelerated share repurchase program and welcomed the updated ESC/EACTS guidelines for Severe Aortic Stenosis. However, the company has been under investigations by
Rosen Law Firm for breaches of fiduciary duties. FTC also opposed EW's acquisition of
JenaValve, citing antitrust concerns. Still, the company holds a promising outlook with its robust TMTT growth expected to drive its Q2 earnings.
Edwards Lifesciences Corp EW News Analytics from Tue, 11 Feb 2025 08:00:00 GMT to Sat, 11 Oct 2025 15:31:21 GMT -
Rating 6
- Innovation -4
- Information 7
- Rumor -2
